Intra-Cellular Therapies Stock Forecast, Price & News

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

Is Intra-Cellular Therapies a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies or view top-rated stocks.

How has Intra-Cellular Therapies' stock price been impacted by COVID-19?

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ITCI stock has increased by 98.1% and is now trading at $35.20.
View which stocks have been most impacted by COVID-19.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decline in short interest in October. As of October 29th, there was short interest totaling 4,210,000 shares, a decline of 21.2% from the October 14th total of 5,340,000 shares. Based on an average daily trading volume, of 441,200 shares, the short-interest ratio is presently 9.5 days. Approximately 5.8% of the shares of the company are sold short.
View Intra-Cellular Therapies' Short Interest.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Intra-Cellular Therapies.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.92) by $0.03. The biopharmaceutical company earned $22.21 million during the quarter, compared to the consensus estimate of $22.11 million. Intra-Cellular Therapies had a negative net margin of 367.06% and a negative trailing twelve-month return on equity of 44.88%. The business's revenue for the quarter was up 201.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.79) earnings per share.
View Intra-Cellular Therapies' earnings history.

What price target have analysts set for ITCI?

8 analysts have issued 12 month price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $38.00 to $70.00. On average, they expect Intra-Cellular Therapies' share price to reach $49.71 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies or view top-rated stocks among Wall Street analysts.

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:

• Sharon Mates, Chairman, President & Chief Executive Officer
• Lawrence J. Hineline, Chief Financial Officer, Treasurer & SVP-Finance
• Robert E. Davis, Chief Scientific Officer & Senior Vice President
• Suresh Durgam, Chief Medical Officer & Senior Vice President
• Karen Patruno Sheehy, Chief Compliance Officer & Senior Vice President

Who are some of Intra-Cellular Therapies' key competitors?

Some companies that are related to Intra-Cellular Therapies include Ono Pharmaceutical (OPHLF), Maravai LifeSciences (MRVI), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), CureVac (CVAC), Jazz Pharmaceuticals (JAZZ), Evotec (EVTCY), Sarepta Therapeutics (SRPT), Grifols (GRFS), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX) and Biohaven Pharmaceutical (BHVN).
View all of ITCI's competitors.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (9.99%), BlackRock Inc. (7.05%), Bellevue Group AG (4.64%), Marshall Wace LLP (2.82%), Lord Abbett & CO. LLC (2.57%) and TimesSquare Capital Management LLC (2.11%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates and Suresh K Durgam.
View institutional ownership trends for Intra-Cellular Therapies.

Which institutional investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Invesco Ltd., Schroder Investment Management Group, Goldman Sachs Group Inc., Lord Abbett & CO. LLC, Jaffetilchin Investment Partners LLC, Franklin Street Advisors Inc. NC, and Avestar Capital LLC. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates, and Suresh K Durgam.
View insider buying and selling activity for Intra-Cellular Therapies or view top insider-selling stocks.

Which institutional investors are buying Intra-Cellular Therapies stock?

ITCI stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., TimesSquare Capital Management LLC, Brandywine Global Investment Management LLC, Credit Suisse AG, Suvretta Capital Management LLC, Candriam Luxembourg S.C.A., Bellevue Group AG, and Russell Investments Group Ltd..
View insider buying and selling activity for Intra-Cellular Therapies or or view top insider-buying stocks.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $35.20.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies has a market capitalization of $2.87 billion and generates $22.81 million in revenue each year. The biopharmaceutical company earns $-227.01 million in net income (profit) each year or ($3.21) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

Intra-Cellular Therapies employs 383 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

Where are Intra-Cellular Therapies' headquarters?

Intra-Cellular Therapies is headquartered at 430 EAST 29TH STREET, NEW YORK NY, 10016.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at [email protected], or via fax at 646-440-9334.